These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26224565)

  • 21. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
    Stewart MW
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases.
    Grimm D; Bauer J; Schoenberger J
    Curr Vasc Pharmacol; 2009 Jul; 7(3):347-57. PubMed ID: 19601859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aflibercept--a decoy VEGF receptor.
    Ciombor KK; Berlin J
    Curr Oncol Rep; 2014 Feb; 16(2):368. PubMed ID: 24445500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the VEGF/VEGFR axis in cancer biology and therapy.
    Rapisarda A; Melillo G
    Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preclinical and clinical review of aflibercept for the management of cancer.
    Gaya A; Tse V
    Cancer Treat Rev; 2012 Aug; 38(5):484-93. PubMed ID: 22264850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
    Jin K; Shen Y; He K; Xu Z; Li G; Teng L
    Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy.
    Sun W
    J Hematol Oncol; 2012 Oct; 5():63. PubMed ID: 23057939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
    Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
    J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.
    Lazzeri S; Ripandelli G; Sartini MS; Parravano M; Varano M; Nardi M; Di Desidero T; Orlandi P; Bocci G
    Angiogenesis; 2015 Oct; 18(4):397-432. PubMed ID: 26346237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
    Chu QS
    Expert Opin Biol Ther; 2009 Feb; 9(2):263-71. PubMed ID: 19236257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
    Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D; Kaiser PK
    Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
    Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.
    Nagy JA; Dvorak HF
    Clin Exp Metastasis; 2012 Oct; 29(7):657-62. PubMed ID: 22692562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.